Fulvestrant (Faslodex&unknown;) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

By Mauriac L.   Pippen J.E.   Quaresma Albano J.   Gertler S.Z.   Osborne C.K.  

European Journal of Cancer, Vol. 39, Iss. 9, 2003-06 ,pp. : 1228-1233

Elsevier

Access to resources Recommend Favorite

Spotlight on Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women with Disease Progression Following Antiestrogen Therapy

By Kate McKeage   Monique P. Curran   Greg L. Plosker  

American Journal of Cancer, Vol. 3, Iss. 4, 2004-01 ,pp. : 267-270

Adis International

Access to resources Recommend Favorite

Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience

By Franco Sandra  

Breast Cancer Research and Treatment, Vol. 88, Iss. 2, 2004-11 ,pp. : 103-108

Springer Publishing Company

Access to resources Recommend Favorite

The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study

By Frechette Dominique   Paquet Lise   Verma Shailendra   Clemons Mark   Wheatley-Price Paul   Gertler Stan   Song Xinni   Graham Nadine   Dent Susan  

Breast Cancer Research and Treatment, Vol. 141, Iss. 1, 2013-08 ,pp. : 111-117

Springer Publishing Company

Access to resources Recommend Favorite

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer

By Dent Susan  

Breast Cancer Research and Treatment, Vol. 126, Iss. 2, 2011-04 ,pp. : 295-310

Springer Publishing Company

Access to resources Recommend Favorite